About this Event
Think of a biotech, or any innovative organization, as a building with a critical foundation, which is trust.
Leaders need to take their trust-building skills to a completely new level to be successful, based on ability, integrity, and generosity. Collective intelligence is the rooftop of this building. Cognitive diversity, social sensitivity of team members, and respectful, candid debate all contribute to intellectual team performance.
Key pillars of success include the creation of high-performing teams, an energized culture characterized by freedom & accountability, a solution-oriented management approach, a focus on various aspects of decision making, peer review, focus, and prioritization.
Finally, engage with potentially disruptive possibilities and foster lateral thinking and creativity.
About the speaker – Paul Peter Tak, MD, PhD, FMedSci
Paul Peter Tak, President, CEO, and Board Director of Candel Therapeutics, Inc.(Needham, MA USA).
Paul Peter received his medical degree cum laude from the Free University in Amsterdam and was trained as an internist, rheumatologist and immunologist at Leiden University Medical Center, where he also received his PhD. He worked as a scientist at the University of California San Diego for two years (1997-1999). He served as Professor of Medicine and founding Chair of the Department of Clinical Immunology and Rheumatology at the Academic Medical Centre/University of Amsterdam (AMC) for 12 years (1999-2011).
He has published extensively in peer-reviewed journals (>575 publications, H-index 134 [Google Scholar], >80,000 citations), received numerous awards, has been elected Fellow of the Academy of Medical Sciences, and was recognized by PharmaVOICE100 (100 most inspiring people in life sciences) in 2021.
At GlaxoSmithKline he served as Senior Vice President, Chief Immunology Officer, and Global Development Leader (2011-2018). He was the Chair of the Scientific Review Board, the governing body accountable for the scientific assessment of GSK’s R&D portfolio. He is also the founder of GSK’s Immunology Network, a collaboration between GSK and leading academics, which provides the latter with cognitive diversity and privileged access to the latest research and facilities GSK has to offer.
He has been President, Founding CEO and Board Director of Kintai Therapeutics (Senda Biosciences) and Venture Partner at Flagship Pioneering (both in Cambridge, MA)(2018-2020).
In September 2020 he became CEO of Candel Therapeutics, where he led the company to an Initial Public Offering (IPO) on the Nasdaq. In addition, he has been Board Director, President and CEO of Tempero Pharmaceuticals (Cambridge, MA) and Board Director of Galvani Bioelectronics, ViiV Healthcare (both in London) and Omega Therapeutics (Cambridge, MA). He is currently on the Board of Sitryx Therapeutics (Co-founder; Oxford), Levicept (London) and Citryll (Oss).